IBDEI0OC ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10843,1,3,0)
 ;;=3^65772
 ;;^UTILITY(U,$J,358.3,10844,0)
 ;;=68135^^76^707^10^^^^1
 ;;^UTILITY(U,$J,358.3,10844,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10844,1,2,0)
 ;;=2^Destruction,Conj Lesion
 ;;^UTILITY(U,$J,358.3,10844,1,3,0)
 ;;=3^68135
 ;;^UTILITY(U,$J,358.3,10845,0)
 ;;=65800^^76^707^11^^^^1
 ;;^UTILITY(U,$J,358.3,10845,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10845,1,2,0)
 ;;=2^Paracentesis of AC
 ;;^UTILITY(U,$J,358.3,10845,1,3,0)
 ;;=3^65800
 ;;^UTILITY(U,$J,358.3,10846,0)
 ;;=66170^^76^707^12^^^^1
 ;;^UTILITY(U,$J,358.3,10846,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10846,1,2,0)
 ;;=2^Fistulization Sclera for Glauc Trabecul
 ;;^UTILITY(U,$J,358.3,10846,1,3,0)
 ;;=3^66170
 ;;^UTILITY(U,$J,358.3,10847,0)
 ;;=67515^^76^707^13^^^^1
 ;;^UTILITY(U,$J,358.3,10847,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10847,1,2,0)
 ;;=2^Inject Tenon's Capsule
 ;;^UTILITY(U,$J,358.3,10847,1,3,0)
 ;;=3^67515
 ;;^UTILITY(U,$J,358.3,10848,0)
 ;;=66030^^76^708^6^^^^1
 ;;^UTILITY(U,$J,358.3,10848,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10848,1,2,0)
 ;;=2^Inj Treatment of Eye,Medication
 ;;^UTILITY(U,$J,358.3,10848,1,3,0)
 ;;=3^66030
 ;;^UTILITY(U,$J,358.3,10849,0)
 ;;=67028^^76^708^7^^^^1
 ;;^UTILITY(U,$J,358.3,10849,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10849,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,10849,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,10850,0)
 ;;=67500^^76^708^11^^^^1
 ;;^UTILITY(U,$J,358.3,10850,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10850,1,2,0)
 ;;=2^Retrobulbar Inj,Medication
 ;;^UTILITY(U,$J,358.3,10850,1,3,0)
 ;;=3^67500
 ;;^UTILITY(U,$J,358.3,10851,0)
 ;;=67505^^76^708^10^^^^1
 ;;^UTILITY(U,$J,358.3,10851,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10851,1,2,0)
 ;;=2^Retrobulbar Inj,Alcohol
 ;;^UTILITY(U,$J,358.3,10851,1,3,0)
 ;;=3^67505
 ;;^UTILITY(U,$J,358.3,10852,0)
 ;;=68200^^76^708^14^^^^1
 ;;^UTILITY(U,$J,358.3,10852,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10852,1,2,0)
 ;;=2^Subconjunctival Injection
 ;;^UTILITY(U,$J,358.3,10852,1,3,0)
 ;;=3^68200
 ;;^UTILITY(U,$J,358.3,10853,0)
 ;;=96372^^76^708^12^^^^1
 ;;^UTILITY(U,$J,358.3,10853,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10853,1,2,0)
 ;;=2^SC/IM Injection
 ;;^UTILITY(U,$J,358.3,10853,1,3,0)
 ;;=3^96372
 ;;^UTILITY(U,$J,358.3,10854,0)
 ;;=96402^^76^708^13^^^^1
 ;;^UTILITY(U,$J,358.3,10854,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10854,1,2,0)
 ;;=2^SQ/IM Anti-Neplastic Hormone Inj
 ;;^UTILITY(U,$J,358.3,10854,1,3,0)
 ;;=3^96402
 ;;^UTILITY(U,$J,358.3,10855,0)
 ;;=J1094^^76^708^4^^^^1
 ;;^UTILITY(U,$J,358.3,10855,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10855,1,2,0)
 ;;=2^Dexamethasone Acetate per 1mg
 ;;^UTILITY(U,$J,358.3,10855,1,3,0)
 ;;=3^J1094
 ;;^UTILITY(U,$J,358.3,10856,0)
 ;;=J3300^^76^708^16^^^^1
 ;;^UTILITY(U,$J,358.3,10856,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10856,1,2,0)
 ;;=2^Triescence per 1mg (use w/ 67028)
 ;;^UTILITY(U,$J,358.3,10856,1,3,0)
 ;;=3^J3300
 ;;^UTILITY(U,$J,358.3,10857,0)
 ;;=J3301^^76^708^8^^^^1
 ;;^UTILITY(U,$J,358.3,10857,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10857,1,2,0)
 ;;=2^Kenalog per 10mg
 ;;^UTILITY(U,$J,358.3,10857,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,10858,0)
 ;;=J3396^^76^708^17^^^^1
 ;;^UTILITY(U,$J,358.3,10858,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,10858,1,2,0)
 ;;=2^Verteporfin/Visudyne per 0.1mg
